Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence

International Angiology

Volumn 24, Issue 1, 2005, Pages 1-26

  Nicolaides, A N ^a   Breddin, H K ^a   Carpentier, P ^a   Coccheri, S ^a   Conard, J ^a   De Stefano, V ^a   Elkoofy, N ^a   Gerotziafas, G ^a   Guermazi, S ^a   Haas, S ^a   Hull, R ^a   Kalodiki, E ^a   Kristof, V ^a   Michiels, J J ^a   Myers, K ^a   Pineo, G ^a   Prandoni, P ^a   Romeo, G ^a   Samama, M M ^a   Simonian, S ^a   Xenophontos, S ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; ANASTROZOLE; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; CHLORMADINONE ACETATE; CONJUGATED ESTROGEN; CONTRACEPTIVE AGENT; DALTEPARIN; DANAPAROID; DESOGESTREL; ENOXAPARIN; ESTRADIOL; ETHINYLESTRADIOL; GESTAGEN; GESTODENE; HEPARIN; HYDROXYUREA; INTERFERON; LEVONORGESTREL; LOW MOLECULAR WEIGHT HEPARIN; MESTRANOL; NORETHISTERONE; NORGESTIMATE; PROGESTERONE; TAMOXIFEN; TINZAPARIN; UNINDEXED DRUG; WARFARIN;

ACTIVATED PROTEIN C RESISTANCE; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONSENSUS; DEEP VEIN THROMBOSIS; DRUG DOSE REGIMEN; FATALITY; GENE FREQUENCY; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HEPARIN INDUCED THROMBOCYTOPENIA; HEREDITY; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; HYPERHOMOCYSTEINEMIA; INCIDENCE; LABORATORY DIAGNOSIS; LOW DRUG DOSE; LUNG EMBOLISM; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; SCREENING TEST; SYSTEMATIC REVIEW; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; ANTIPHOSPHOLIPID SYNDROME; EUROPE; FACTOR V; FACTOR VIII; HORMONE REPLACEMENT THERAPY; HUMANS; HYPERHOMOCYSTEINEMIA; MUTATION; PROTEIN S; RECURRENCE; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 33645046565     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (310)

1. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V et al. Inherited thrombophilia: Part 1. Thromb Haemost 1996;76:651-62.
2. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V et al. Inherited thrombophilia: Part 2. Thromb Haemost 1996;76:824-34.
3. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-73.
4. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001;344:1222-31.
5. Samama MM, Conard J, Toulemonde F. Coagulation abnormalities predisposing to the development of deep vein thrombosis, in deep vein thrombosis. In: Bergqvist DCA, Nicolaides A, Scurr J, editors. Prevention of venous thromboembolism. London: Med-Orion; 1994.p.43-56.
6. Greaves M, Baglin T. Laboratory testing for heritable thrombophilia: impact on clinical management of thrombotic disease annotation. Br J Haematol 2000;109:699-703.
7. Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. Br Med J 1991;302:709-11.
8. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A. The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med 1992;152:1660-4.
9. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992;232:155-60.
10. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999;159:445-53.
11. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ 3rd. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160: 761-8.
12. Nelzen O, Bergqvist D, Lindhagen A. Leg ulcer etiology - a cross sectional population study. J Vasc Surg 1991;14: 557-64.
13. Nelzen O, Bergqvist D, Lindhagen A, Hallbook T. Chronic leg ulcers: an underestimated problem in primary health care among elderly patients. J Epidemiol Community Health 1991;45:184-7.
14. Callam MJ, Harper DR, Dale JJ, Ruckley CV. Chronic ulcer of the leg: clinical history. Br Med J (Clin Res Ed) 1987;294:1389-91.
15. Jantet G. The socioeconomic impact of venous pathology in Great Britain. Phlebologie 1992;45:433-7.
16. Hume M. Venous ulcers, the vascular surgeon, and the Medicare budget. J Vasc Surg 1992;16:671-3.
17. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353:1386-9.
18. Kearon C, Ginsberg JS, Hirsh J. The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med 1998;129:1044-9.
19. van Strijen MJ, de Monye W, Schiereck J, Kieft GJ, Prins MH, Huisman MV et al. Single-detector helical computed tomography as the primary diagnostic test in suspected pulmonary embolism: a multicenter clinical management study of 510 patients. Ann Intern Med 2003;138:307-14.
20. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:338S-400S.
21. Kearon C. Epidemiology of venous thromboembolism. Sem Vasc Med 2001;1:7-25.
22. Kakkar VV, Howe CT, Nicolaides AN, Renney JT, Clarke MB. Deep vein thrombosis of the leg. Is there a "high risk" group? Am J Surg 1970;120:527-30.
23. Clayton JK, Anderson JA, McNicol GP. Preoperative prediction of postoperative deep vein thrombosis. Br Med J 1976;2:910-2.
24. Havig O. Deep vein thrombosis and pulmonary embolism. An autopsy study with multiple regression analysis of possible risk factors. Acta Chir Scand Suppl 1977;478: 1-120.
25. Lowe GD, Carter DC, Prentice CR. Preoperative prediction of postoperative deep-vein thrombosis. Lancet 1982;1:1474.
26. Sue-Ling HM, Johnston D, McMahon MJ, Philips PR, Davies JA. Preoperative identification of patients at high risk of deep venous thrombosis after elective major abdominal surgery. Lancet 1986;1:1173-6.
27. Campbell B. Thrombosis, phlebitis, and varicose veins. Br Med J 1996;312:198-9.
28. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977-80.
29. Daly E, Vessey MP, Painter R, Hawkins MM. Case-control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet 1996;348:1027.
30. Goldhaber SZ, Grodstein F, Stampfer AU, Manson JE, Colditz GA, Speizer FE et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997;277:642-5.
31. Lowe GD, Haverkate F, Thompson SG, Turner RM, Bertina RM, Turpie AG et al. Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT Study. European Concerted Action on Thrombosis. Thromb Haemost 1999;81:879-86.
32. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-15.
33. Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost 2002;88:407-14.
34. Eichinger S, Weltermann A, Minar E, Stain M, Schonauer V, Schneider B et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med 2004;164:92-6.
35. Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002;162: 1245-8.
36. Samama MM, Dahl OE, Quinlan DJ, Mismetti P, Rosencher N. Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. Haematologica 2003;88:1410-21.
37. Nicolaides AN, Breddin HK, Fareed J, Goldhaber S, Haas S, Hull R et al. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 2001;20:1-37.
38. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999;341:793-800.
39. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982;10:448-50.
40. Moser KM, LeMoine JR, Nachtwey FJ, Spragg RG. Deep venous; thrombosis and pulmonary embolism. Frequency in a respiratory intensive care unit. JAMA 1981;246: 1422-4.
41. Fraisse F, Holzapfel L, Couland JM, Simonneau G, Bedock B, Feissel M et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 2000;161:1109-14.
42. Kapur M, Kupfer Y, Tessler S. Subcutaneous heparin prophylaxis significally reduces the incidence of venous thromboembolic events in the critically ill [abstract]. Crit Care Med 1999;27 Suppl:A69.
43. Kakkar VV, Howe CT, Flanc C, Clarke MB. Natural history of postoperative deep-vein thrombosis. Lancet 1969;2:230-2.
44. Partsch H, Blattler W. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. J Vasc Surg 2000;32:861-9.
45. Diener L. Intraosseous phlebography of the lower limb. Postmortem investigation of thrombotic venous disease. Acta Radiol Diagn (Stockh) 1971:Suppl 304:1-96.
46. Philbrick JT, Becker DM. Calf deep venous thrombosis. A wolf in sheep's clothing? Arch Intern Med 1988;148: 2131-8.
47. IMT. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. Lancet 1975;2:45-51.
48. Lohr JM, Kerr TM, Lutter KS, Cranley RD, Spirtoff K, Cranley JJ. Lower extremity calf thrombosis: to treat or not to treat? J Vasc Sur. 1991;14:618-23.
49. Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994;72:191-7.
50. Levine AIN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995;74:606-11.
51. Schulman S, Lindmarker P, Johnsson H. Influence of changes in lifestyle on fibrinolytic parameters and recurrence rate in patients with venous thromboembolism. Blood Coagul Fibrinolysis 1995;6:311-6.
52. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
53. Bernardi E, Bagatella P, Frulla M, Simioni P, Prandoni P. Post-thrombotic syndrome: incidence, prevention and management. Sem Vasc Med 2001;1:71-79.
54. Bollinger A, Leu AJ, Hoffmann U, Franzeck UK. Microvascular changes in venous disease: an update. Angiology 1997;48:27-32.
55. Nicolaides AN. Investigation of chronic venous insufficiency. A consensus statement. Circulation 2000;102: e126-63.
56. O'Donnell TF Jr, Browse NL, Burnand KG, Thomas ML. The socioeconomic effects of an iliofemoral venous thrombosis. J Surg Res 1977;22:483-8.
57. Strandness DE Jr, Langlois Y, Cramer M, Randlett A, Thiele BL. Long-term sequelae of acute venous thrombosis. JAMA 1983;250:1289-92.
58. Lindhagen A, Bergqvist A, Bergqvist D, Hallbook T. Late venous function in the leg after deep venous thrombosis occurring in relation to pregnancy. Br J Obstet Gynaecol 1986;93:348-52.
59. Lindner DJ, Edwards JM, Phinney ES, Taylor LM Jr, Porter JM. Long-term hemodynamic and clinical sequelae of lower extremity deep vein thrombosis. J Vasc Surg 1986;4:436-42.
60. Norris CS, Darrow JM. Hemodynamic indicators of post-thrombotic sequelae. Arch Surg 1986;121:765-8.
61. Akesson H, Brudin L, Dahlstrom JA, Eklof B, Ohlin P, Plate G. Venous function assessed during a 5 year period after acute ilio-femoral venous thrombosis treated with anticoagulation. Eur J Vasc Surg 1990;4:43-8.
62. Bergqvist D. Prophylaxis against postoperative venous thromboembolism - a survey of surveys. Thromb Haemorrh Disorders 1990;2:69-73.
63. Heldal M, Seem E, Sandset PM, Abildgaard U. Deep vein thrombosis: a 7-year follow-up study. J Intern Med 1993;234:71-5.
64. Milne AA, Ruckley CV. The clinical course of patients following extensive deep venous thrombosis. Eur J Vasc Surg 1994;8:56-9.
65. van Ramshorst B, van Bemmelen PS, Hoeneveld H, Eikelboom BC. The development of valvular incompetence after deep vein thrombosis: a follow-up study with duplex scanning. J Vasc Surg 1994;19:1059-66.
66. van Haarst EP, Liasis N, van Ramshorst B, Moll FL. The development of valvular incompetence after deep vein thrombosis: a 7 year follow-up study with duplex scanning. Eur J Vasc Endovasc Surg 1996;12:295-9.
67. Elliot MS, Immelman EJ, Jeffery P, Benatar SR, Funston MR, Smith JA et al. The role of thrombolytic therapy in the management of phlegmasia caerulea dolens. Br J Surg 1979;66:422-4.
68. Browse NL, Clemenson G, Thomas ML. Is the post-phlebitic leg always postphlebitic? Relation between phlebographic appearances of deep-vein thrombosis and late sequelae. Br Med J 1980;281:1167-70.
69. Kakkar VV, Lawrence D. Hemodynamic and clinical assessment after therapy for acute deep vein thrombosis. A prospective study. Am J Surg 1985;150:54-63.
70. Markel A, Manzo RA, Bergelin RO, Strandness DE Jr. Pattern and distribution of thrombi in acute venous thrombosis. Arch Surg 1992;127:305-9.
71. Johnson BF, Manzo RA, Bergelin RO, Strandness DE Jr. Relationship between changes in the deep venous system and the development of the postthrombotic syndrome after an acute episode of lower limb deep vein thrombosis: a one- to six-year follow-up. J Vasc Surg 1995;21:307-12; discussion 313.
72. Prandoni P, Piccioli A, Pagnan A. Recurrent thromboembolism in cancer patients: incidence and risk factors. Semin Thromb Hemost 2003;29 Suppl 1:3-8.
73. van Dongen CJ, Vink R, Hutten BA, Buller HR, Prins MH. The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch Intern Med 2003;163:1285-93.
74. Ageno W, Piantanida E, Dentali F, Mera V, Squizzato A, Marchesi C et al. Weight gain after acute deep venous thrombosis: a prospective observational study. Thromb Res 2003;109:31-5.
75. Franzeck UK, Schalch I, Jager KA, Schneider E, Grimm J, Bollinger A. Prospective 12-year follow-up study of clinical and hemodynamic sequelae after deep vein thrombosis in low-risk patients (Zurich study). Circulation 1996;93:74-9.
76. Brandjes DP, Buller HR, Heijboer H, Huisman MV, de Rijk M, Jagt H et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997;349:759-62.
77. Skene AI, Smith JM, Dore CJ, Charlett A, Lewis JD. Venous leg ulcers: a prognostic index to predict time to healing. Br Med J 1992;305:1119-21.
78. Prandoni P, Piccioli A, Girolami A. Cancer and venous thromboembolism: an overview. Haematologica 1999;84; 437-45.
79. Prandoni P. Cancer and thromboembolic disease: how important is the risk of thrombosis? Cancer Treat Rev 2002;28:133-6.
80. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285-91.
81. Ferrari E, Chevallier T, Chapelier A, Baudouy M. Travel as a risk factor for venous thromboembolic disease: a case-control study. Chest 1999;115:440-4.
82. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000;160:3415-20.
83. Lapostolle F, Surget V, Borron SW, Desmaizieres M, Sordelet D, Lapandry C et al. Severe pulmonary embolism associated with air travel. N Engl J Med 2001;345:779-83.
84. Scurr JH, Smith PD, Machin S. Deep vein thrombosis in airline passengers - the incidence of deep vein thrombosis and the efficacy of elastic compression stockings. Cardiovasc Surg 2001;9:159-61.
85. Scurr JH, Machin SJ, Bailey-King S, Mackie IJ, McDonald S, Smith PD. Frequency and prevention of symptomless deep-vein thrombosis in long-haul flights: a randomised trial. Lancet 2001;357:1485-9.
86. Belcaro G, Geroulakos G, Nicolaides AN, Myers KA, Winford M. Venous thromboembolism from air travel: the LONFLIT study. Angiology 2001;52:369-74.
87. Parsi KA, McGrath MA, Lord RS. Traveller's venous thromboembolism. Cardiovasc Surg 2001;9:157-8.
88. Legnani C, Cosmi B, Valdre L, Boggian O, Bernardi F, Coccheri S et al. Venous thromboembolism, oral contraceptives and high prothrombin levels. J Thromb Haemost 2003;1:112-7.
89. Egeberg O. Inherited Antithrombin Deficiency Causing Thrombophilia. Thromb Diath Haemorrh 1965;13:516-30.
90. Bertina RM, van der Linden IK, Engesser L, Muller HP, Brommer EJ. Hereditary heparin cofactor II deficiency and the risk of development of thrombosis. Thromb Haemost 1987;57:196-200.
91. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
92. Engesser L, Broekmans AW, Briet E, Brommer EJ, Bertina RM. Hereditary protein S deficiency: clinical manifestations. Ann Intern Me. 1987;106:677-82.
93. Grandone E, Margaglione M, Colaizzo D, D'Andrea G, Cappucci G, Brancaccio V et al. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol 1998;179:1324-8.
94. Bauer KA, Broekmans AW, Bertina RM, Conard J, Horellou MH, Samama MM et al. Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. Blood 1988;71:1418-26.
95. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993;90:1004-8.
96. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-22.
97. Trossaert M, Conard J, Horellou MH, Samaha M, Elalamy I, Samama MM. Resistance to activated protein C in venous thromboembolic complications. Incidence and clinical manifestations. Presse Med 1995;24:209-12.
98. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
99. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000;343:457-62.
100. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
101. Zivelin A, Griffin JH, Xu X, Pabinger I, Samama M, Conard J et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 1997;89:397-402.
102. Zivelin A, Rosenberg N, Faier S, Kornbrot N, Peretz H, Mannhalter C et al. A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood 1998;92:1119-24.
103. Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998;91:1135-9.
104. Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306→Thr) associated with resistance to activated protein C. Blood 1998;91:1140-4.
105. Lane DA, Bayston T, Olds RJ, Fitches AC, Cooper DN Millar DS et al. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997;77:197-211.
106. Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet 2001;109:369-84.
107. Kearon C, Crowther M, Hirsh J. Management of patients with hereditary hypercoagulable disorders. Annu Rev Med 2000;51:169-85.
108. van Boven HH, Vandenbroucke JP, Briet E, Rosendaal FR. Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited antithrombin deficiency. Blood 1999;94:2590-4.
109. Reitsma PH. On-line database available at www.xl4all.nl/~reitsma/Prot_C_home.htm.
110. Seligsohn U, Berger A, Abend M, Rubin L, Attias D, Zivelin A et al. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med 1984;310:559-62.
111. Marlar RA, Montgomery RR, Broekmans AW. Report on the diagnosis and treatment of homozygous protein C deficiency. Report of the Working Party on Homozygous Protein C Deficiency of the ICTH-Subcommittee on Protein C and Protein S. Thromb Haemost 1989;61:529-31.
112. Conard J, Horellou MH, van Dreden P, Samama M, Reitsma. PH, Poort S et al. Homozygous protein C deficiency with late onset and recurrent coumarin-induced skin necrosis. Lancet 1992;339:743-4.
113. Gandrille S, Borgel D, Sala N, Espinosa-Parrilla Y, Simmonds R, Rezende S et al. Protein S deficiency: a database of mutations - summary of the first update. Thromb Haemost 2000;84:918.
114. Hackeng TM, van't Veer C, Meijers JC, Bouma BN. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem 1994;269: 21051-8.
115. Faloni EM, Valsecchi C, Palla A, Taioli E, Razzari C, Mannucci PM. Free protein S deficiency is a risk factor for venous thrombosis. Thromb Haemost 1997;78: 1343-6.
116. Israels SJ, Seshia SS. Childhood stroke associated with protein C or S deficiency. J Pediatr 1987;111:562-4.
117. Pierre-Jacques H, Glueck CJ, Mont MA, Hungerford DS. Familial heterozygous protein-S deficiency in a patient who had multifocal osteonecrosis. A case report. J Bone Joint Surg Am 1997;79:1079-84.
118. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999;19:700-3.
119. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997;90:1747-50.
120. Austin RC, Lentz SR, Werstuck GH. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ 2004;11 Suppl 1:S56-64.
121. den Heijer M. Hyperhomocysteinaemia as a risk factor for venous thrombosis: an update of the current evidence. Clin Chem Lab Med 2003;41:1404-7.
122. Pineo GF, Hull RD. Thrombophilia: disorders predisposing to venous thromboembolism. Baillieres Clin Haematol 1998;11:525-40.
123. Kyrle PA. High factor VIII and the risk of venous thromboembolism. Hamostaseologie 2003;23:41-4.
124. Legnani C, Cosmi B, Cini M, Frascaro M, Guazzaloca G, Palareti G. High plasma levels of factor VIII and risk of recurrence of venous thromboembolism. Br J Haematol 2004;124:504-10.
125. Weltermann A, Eichinger S, Bialonczyk C, Minar E, Hirschl M, Quehenberger P et al. The risk of recurrent venous; thromboembolism among patients with high factor IX levels. J Thromb Haemost 2003;1:28-32.
126. Tripodi A. Levels of coagulation factors and venous thromboembolism. Haematologica 2003;88:705-11.
127. Kostka H, Kuhlisch E, Schellong S, Siegert G. Polymorphisms in the TAFI gene and the risk of venous thrombosis. Clin Lab 2003;49:645-7.
128. Franco RF, Fagundes MG, Meijers JC, Reitsma PH, Lourenco D, Morelli V et al. Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 2001;86:510-7.
129. Eichinger S, Schonauer V, Weltermann A, Minar E, Bialonczyk C, Hirschl M et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004; 103:3773-6.
130. Lechner K, Korninger C, Kyrle P, Geissler K, Niessner H, Pabinger I et al. Oral anticoagulant therapy - renaissance of an old therapy? Wien Klin Wochenschr 1987;99:203-10.
131. Triplett DA. Antiphospholipid antibodies, lupus anticoagulants and thromboembolic disease. Haematologica 1995;80:122-6.
132. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992;117:997-1002.
133. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404-7.
134. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga. A et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886-9.
135. Piccioli A, Vianello F, Prandoni P. Management of thrombosis in patients with hematologic malignancies. Curr Hematol Rep 2002;1:79-83.
136. Donati MB, Falanga A. Pathogenetic mechanisms of thrombosis in malignancy. Acta Haematol 2001;106:18-24.
137. Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet 1998;351:1077-80.
138. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998;338:1169-73.
139. Girolami A, Prandoni P, Zanon E, Bagatella P, Girolami B. Venous thromboses of upper limbs are more frequently associated with occult cancer as compared with those of lower limbs. Blood Coagul Fibrinolysis 1999;10: 455-7.
140. Prandoni P, Lensing AW, Buller HR, Cogo A, Prins MH, Cattelan AM et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327:1128-33.
141. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998;104:332-8.
142. Ichikawa K, Tsutsumi A, Matsuura E, Koike T. Antiphospholipid syndrome. Intern Med 1999;38:170-3.
143. Alhenc-Gelas M. The biological distribution of thrombosis in the year 2000. Gynecol Obstet Fertil 2001;29:841-5.
144. Passam F, Krilis S. Laboratory tests for the antiphospholipid syndrome: current concepts. Pathology 2004;36:129-38.
145. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003;102:2717-23.
146. Zanon E, Saggiorato G, Ramon R, Girolami A, Pagnan A, Prandoni P. Anti-prothrombin antibodies as a potential risk factor of recurrent venous thromboembolism. Thromb Haemost 2004;91:255-8.
147. Ruggeri M, Gisslinger H, Tosetto A, Rintelen C, Mannhalter C, Pabinger I et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 2002;71:1-6.
148. Jensen MK, de Nully Brown P, Thorsen S, Hasselbalch HC. Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders. Am J Hematol 2002;69:185-91.
149. Mohanty D, Shetty S, Ghosh K, Pawar A, Abraham P. Hereditary thrombophilia as a cause of Budd-Chiari syndrome: a study from Western India. Hepatology 2001;34:666-70.
150. Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000;96:2364-8.
151. Griesshammer M, Bangerter M, van Vliet HH, Michiels JJ. Aspirin in essential thrombocythemia: status quo and quo vadis. Semin Thromb Hemost 1997;23:371-7.
152. Michiels JJ, Abels J, Steketee J, van Vliet HH, Vuzevski VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 1985;102:466-71.
153. Scheffer MG, Michiels JJ, Simoons ML, Roelandt JR. Thrombocythemia and coronary artery disease. Am Heart J 1991;122:573-6.
154. Michiels JJ, Koudstaal PJ, Mulder AH, van Vliet HH. Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology 1993;43:1107-10.
155. van Genderen PJ, Michiels JJ, van Strik R, Lindemans J, van Vliet HH. Platelet consumption in thrombocythemia complicated by crythromelalgia: reversal by aspirin. Thromb Haemost 1995;73:210-4.
156. van Genderen PJ, Mulder PG, Waleboer M, van de Moesdijk D, Michiels JJ. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol 1997;97:179-84.
157. Koudstaal PJ, Koudstaal A. Neurologic and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin. Semin Thromb Hemost 1997;23:365-70.
158. Barabas AP, Offen DN, Meinhard EA. The arterial complications of polycythaemia vera. Br J Surg 1973;60:183-7.
159. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med 1995;123:656-64.
160. Michiels JJ, Berneman ZN, Schroyens W, Van Vliet HH. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Platelets 2004;15:67-84.
161. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-24.
162. Angelopoulou K, Nicolaides A, Constantinou Deltas C. Prevalence of genetic mutations that predispose to thrombophilia in a Greek Cypriot population. Clin Appl Thromb Hemost 2000;6:104-7.
163. Abdulkadir J, Feleke Y, Berg JP, Falch JA, Odegaard OR. Absence of the factor V Leiden mutation in Ethiopians. Thromb Res 1997;86:431-2.
164. Irani-Hakime N, Tamim H, Kreidy R, Almawi WY. The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese. Am J Hematol 2000;65: 45-9.
165. Awidi A, Shannak M, Bseiso A, Kailani MA, Omar N, Anshasi B et al. High prevalence of factor V Leiden in healthy Jordanian Arabs. Thromb Haemost 1999;81: 582-4.
166. Eid SS. Hereditary deficiencies of antithrombin III, protein S, and the protein C pathway in Jordanian thrombosis patients. Clin Lab Sci 2002;15:196-9.
167. Lambropoulos AF, Foka Z, Makris M, Daly M, Kotsis A, Makris PE. Factor V Leiden in Greek thrombophilic patients: relationship with activated protein C resistance test and levels of thrombin-antithrombin complex and prothrombin fragment 1+2. Blood Coagul Fibrinolysis 1997;8:485-9.
168. Antoniadi T, Hatzis T, Kroupis C, Economou-Petersen E, Petersen MB. Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in a Greek population of blood donors. Am J Hematol 1999;61:265-7.
169. Zalavras Ch G, Giotopoulou S, Dokou E, Mitsis M, Ioannou HV, Tsaousi C et al. Prevalence of the G20210A prothrombin gene mutation in Northwestern Greece and association with venous thromboembolism. Int Angiol 2003;22:55-7.
170. Demir M, Vural O, Sunar H, Altun A, Yorulmaz F, Ozbay G. The prevalence of hereditary thrombophilia in the Trakya region of Turkey. Yonsei Med J 2000;41:436-40.
171. Gurgey A, Haznedaroglu IC, Egesel T, Buyukasik Y, Ozcebe OI, Sayinalp N et al. Two common genetic thrombotic risk factors: factor V Leiden and prothrombin G20210A in adult Turkish patients with thrombosis. Am J Hematol 2001;67:107-11.
172. Rosen E, Renbaum, P, Heyd J, Levy-Lahad E. High frequency of factor V Leiden in a population of Israeli Arabs. Thromb Haemost 1999;82:1768.
173. Al-Jaouni SK. Primary thrombophilia in Saudi Arabia. Saudi Med J 2003;24:614-6.
174. Zeinali S, Duca F, Zarbakhsh B, Tagliabue L, Mannucci PM. Thrombophilic mutations in Iran. Thromb Haemost 2000;83:351-2.
175. Frere C, Saut N, Boukef MK, Zili M, Tourni NE. Factor V Leiden G1691A and prothrombin G20210A mutations are common in Tunisia. J Thromb Haemost 2003;1:2451-2.
176. Helley D, Chafa O, Yaker NL, Reghis A, Fischer AM. Prevalence of the prothrombin gene 20210A mutation in thrombophilic and healthy Algerian subjects. Thromb Haemost 1999;82:1554-5.
177. Mathonnet F, Nadifi S, Serazin-Leroy V, Dakouane M, Giudicelli Y. Absence of factor V Leiden mutation and low prothrombin G 20210 A mutation prevalence in a healthy Moroccan population. Thromb Haemost 2002;88:1073-4.
178. Irani-Hakime N, Tamim H, Elias G, Choueiry S, Kreidy R, Daccache JL et al. Factor V R506Q mutation-Leiden: an independent risk factor for venous thrombosis but not coronary artery disease. J Thromb Thrombolysis 2001;11:111-6.
179. Xenophontos SL, Hadjivassiliou M, Ayrton N, Karagrigoriou A, Pantzaris M, Nicolaides AN et al. Spectrum and prevalence of prothrombotic single nucleotide polymorphism profiles in the Greek Cypriot population. Int Angiol 2002;21:322-9.
180. Margaglione M, Brancaccio V, De Lucia D, Martinelli I, Ciampa A, Grandone E et al. Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism. Chest 2000;118:1405-11.
181. Garcia-Gala JM, Alvarez V, Pinto CR, Soto I, Urgelles MF, Menendez MJ et al. Factor V Leiden (R506Q) and risk of venous; thromboembolism: a case-control study based on the Spanish population. Clin Genet 1997;52:206-10.
182. Santamaria A, Mateo J, Oliver A, Menendez B, Souto JC, Borrell M et al. Risk of thrombosis associated with oral contraceptives of women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene. Haematologica 2001;86:965-71.
183. Braun A, Muller B, Rosche AA. Population study of the G1691A mutation (R5060, FV Leiden) in the human factor V gene that is associated with resistance to activated protein C. Hum Genet 1996;97:263-4.
184. Schroder W, Koesling M, Wulff K, Wehnert M, Herrmann FH. Large-scale screening for factor V Leiden mutation in a north-eastern German population. Haemostasis 1996;26:233-6.
185. Holm J, Zoller B, Berntorp E, Erhardt L, Dahlback B. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries. J Intern Med 1996;239:221-6.
186. Zoller B, Norlund L, Leksell H, Nilsson JE, von Schenck H, Rosen U et al. High prevalence of the FVR506Q mutation causing APC resistance in a region of southern Sweden with a high incidence of venous thrombosis. Thromb Res 1996;83:475-7.
187. Svensson PJ, Zoller B, Mattiasson I, Dahlback B. The factor VR506Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis. J Intern Med 1997;241:379-85.
188. Takamiya O, Ishida F, Kodaira H, Kitano K. APC-resistance and Mnl I genotype (Gln 506) of coagulation factor V are rare in Japanese population. Thromb Haemost 1995;74:996-1002.
189. de Maat MP, Kluft C, Jespersen J, Gram J. World distribution of factor V Leiden mutation. Lancet 1996;347:58.
190. Hatzis T, Cardamakis E, Drivalas E, Makatsoris K, Bevan D, Pantos C et al. Increased resistance to activated protein C and factor V Leiden in recurrent abortions. Review of other hypercoagulability factors. Eur J Contracept Reprod Health Care 1999;4:135-44.
191. Cox MJ, Rees DC, Martinson JJ, Clegg JB. Evidence for a single origin of factor V Leiden. Br J Haematol 1996;92:1022-5.
192. Zoller B, Hillarp A, Dahlback B. Activated protein C resistance caused by a common factor V mutation has a single origin. Thromb Res 1997;85:237-43.
193. Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998;79:706-8.
194. Gurgey A, Mesci L. The prevalence of factor V Leiden (1691 G→A) mutation in Turkey. Turk J Pediatr 1997;39:313-5.
195. Balta G, Gurgey A. Methylenetetrahydrofolate reductase (MTHFR) C677T mutation in Turkish patients with thrombosis. Turk J Pediatr 1999;41:197-9.
196. Zalavras Ch G, Giotopoulou S, Dokou E, Mitsis M, Ioannou HV, Tzolou A et al. Lack of association between the C677T mutation in the 5,10-methylenetetrahydrofolate reductase gene and venous thromboembolism in Northwestern Greece. Int Angiol 2002;21:268-71.
197. Ben-Tal O, Zivelin A, Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemost 1989;61: 50-4.
198. Tripodi A, Mannucci PM. Laboratory investigation of thrombophilia. Clin Chem 2001;47:1597-606.
199. Persson KE, Dahlback B, Hillarp A. Diagnosing protein S deficiency: analytical considerations. Clin Lab 2003;49: 103-10.
200. Goodwin AJ, Rosendaal FR, Kottke-Marchant K, Bovill EG. A review of the technical, diagnostic, and epidemiologic considerations for protein S assays. Arch Pathol Lab Med 2002;126:1349-66.
201. Jorquera JI, Montoro JM, Fernandez MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994;344:1162-3.
202. Trossaert M, Conard J, Horellou MH, Samama MM, Ireland H, Bayston TA et al. Modified APC resistance assay for patients on oral anticoagulants. Lancet 1994;344:1709.
203. van Oerle R, van Pampus L, Tans G, Rosing J, Hamulyak K. The clinical application of a new specific functional assay to detect the factor V (Leiden) mutation associated with activated protein C resistance. Am J Clin Pathol 1997;107:521-6.
204. Maessen-Visch MB, Hamulyak K, Tazelaar DJ, Crombag NH, Neumann HA. The prevalence of factor V Leiden mutation in patients with leg ulcers and venous insufficiency. Arch Dermatol 1999;135:41-4.
205. Gaber Y, Siemens HJ, Schmeller W. Resistance to activated protein C due to factor V Leiden mutation: high prevalence in patients with post-thrombotic leg ulcers. Br J Dermatol 2001;144:546-8.
206. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.
207. Walker ID. Venous and arterial thrombosis during pregnancy: epidmiology. Sem Vasc Med 2003;3:25-32.
208. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001;344:1527-35.
209. Hannaford PC, Owen-Smith V. Using epidemiological data to guide clinical practice: review of studies on cardiovascular disease and use of combined oral contraceptives. Br Med J 1998;316:984-7.
210. Bloemenkamp KW, Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. Venous thrombosis, oral contraceptives and high factor VIII levels. Thromb Haemost 1999;82:1024-7.
211. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593-6.
212. Contraception WCsoCDasH. Effect of different progestogens in low dose oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1593-6.
213. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. Br J Med 1996;312:83-8.
214. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-93.
215. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Br Med J 2001;323:131-4.
216. Lidegaard O, Edstrom. B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002;65:187-96.
217. Tans G, Bouma BN, Buller HR, Rosing J. Changes of hemostatic variables during oral contraceptive use. Sem Vasc Med 2003;3:61-8.
218. Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 2002;81:482-90.
219. Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999;354:1610-1.
220. Conard J, Plu-Bureau G, Bahi N, Horellou MH, Pelissier C, Thalabard JC. Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception 2004;70:437-41.
221. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998;338: 1793-7.
222. Martinelli I. Unusual forms of venous thrombosis and thrombophilia. Pathophysiol Haemost Thromb 2002;32: 343-5.
223. Legnani C, Palareti G, Guazzaloca G, Cosmi B, Lunghi B, Bernardi F et al. Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use. Eur Heart J 2002;23:984-90.
224. Girolami A, Simioni P, Girolami B, Zanardi S. The role of drugs, particularly oral contraceptives, in triggering thrombosis in congenital defects of coagulation inhibitors: a study of six patients. Blood Coagul Fibrinolysis 1991;2:673-8.
225. Simioni P, Sanson BJ, Prandoni P, Tormene D, Friederich PW, Girolami B et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999;81:198-202.
226. Pabinger I, Schneider B. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. Thromb Haemost 1994;71:548-52.
227. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995;345:152-5.
228. O'Donnell J, Tuddenham EG, Manning R, Kemball-Cook G, Johnson D, Laffan M. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 1997;77:825-8.
229. O'Donnell J, Mumford AD, Manning RA, Laffan M. Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost 2000;83:10-3.
230. Kraaijenhagen RA, in't Anker PS, Koopman MM, Reitsma PH, Prins MH, van den Ende A et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000;83:5-9.
231. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000;160:49-52.
232. Vasilakis C, Jick SS, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception 1999;59:79-83.
233. Macik BG, Rand JH, Konkle BA. Thrombophilia: what's a practitioner to do? Hematology (Am Soc Hematol Educ Program) 2001:322-38.
234. Oger E, Scarabin PY. Assessment of the risk for venous thromboembolism among users of hormone replacement therapy. Drugs Aging 1999;14:55-61.
235. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002;360:942-4.
236. Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy-results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000;84:961-7.
237. Rosendaal FR, Vessey M, Rumley A, Daly E, Woodward M, Helmerhorst FM et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002;116:851-4.
238. Herrington DM, Vittinghoff E, Howard TD, Major DA, Owen J, Reboussin DM et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol 2002;22:1012-7.
239. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-32.
240. Oger E, Alhenc-Gelas M, Lacut K, Blouch MT, Roudaut N, Kerlan V et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003;23:1671-6.
241. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997;17:3071-8.
242. Lowe GD, Upton MN, Rumley A, McConnachie A, O'Reilly DS, Watt GC. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein - a cross-sectional population survey. Thromb Haemost 2001;86:550-6.
243. De Mitrio V, Marino R, Cicinelli E, Galantino P, Di Bari L, Giannoccaro F et al. Beneficial effects of post-menopausal hormone replacement therapy with transdermal estradiol on sensitivity to activated protein C. Blood Coagul Fibrinolysis 2000;11:175-82.
244. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619-25.
245. Kessler CM, Szymanski LM, Shamsipour Z, Muesing RA, Miller VT, LaRosa JC. Estrogen replacement therapy and coagulation: relationship to lipid and lipoprotein changes. Obstet Gynecol 1997;89:326-31.
246. Habiba M, Andrea A, Phipps B, al-Azzawi F. Thrombophilia and lipid profile in postmenopausal women using a new transdermal oestradiol patch. Eur J Obstet Gynecol Reprod Biol 1996;66:165-8.
247. Glueck CJ, Phillips HG, Cameron D, Wang P. Estrogen replacement in a protein S deficient patient leads to diarrhea, hyperglucagonemia, and osteonecrosis. Jop 2001;2:323-9.
248. Caine YG, Bauer KA, Barzegar S, ten Cate H, Sacks FM, Walsh BW et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992;68:392-5.
249. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. The Writing Group for the Estradiol Clotting Factors Study. Thromb Haemost 1996;75: 476-80.
250. Glueck CJ, McMahon RE, Bouquot JE, Triplett D, Gruppo R, Wang P. Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens. J Lab Clin Med 1997;130:540-3.
251. Glueck CJ, McMahon RE, Bouquot JE, Triplett D. Exogenous estrogen may exacerbate thrombophilia, impair bone healing and contribute to development of chronic facial pain. Cranio 1998;16:143-53.
252. Glueck CJ, Wang P, Fontaine RN, Tracy T, Sieve-Smith L, Lang JE. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C. Am J Cardiol 1999;84:549-54.
253. Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999;25:137-45.
254. Bonneterre J, Thurlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748-57.
255. McColl MD, Walker ID, Greer IA. The role of inherited thrombophilia in venous thromboembolism associated with pregnancy. Br J Obstet Gynaecol 1999;106:756-66.
256. McColl MD, Walker ID, Greer IA. Risk factors for venous thromboembolism in pregnancy. Curr Opin Pulm Med 1999;5:227-32.
257. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001;119:122S-131S.
258. Conard J, Horellou MH, Samama MM. Inherited thrombophilia and gestational venous thromboembolism. Semin Thromb Hemost 2003;29:131-42.
259. Conard J. Thrombophilia and pregnancy: who should be tested? Which tests should be performed? The biologist point of view. Ann Med Interne (Paris) 2003;154: 340-4.
260. Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999;81:668-72.
261. Lepercq J, Conard J, Borel-Derlon A, Darmon JY, Boudignat O, Francoual C et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. Br J Obstet Gynaecol 2001;108: 1134-40.
262. Pettila V, Kaaja R, Leinonen P, Ekblad U, Kataja M, Ikkala E. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thromb Res 1999;96:275-82.
263. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160:769-74.
264. Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 2000;160:3431-6.
265. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998;279:458-62.
266. Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-14.
267. Brandjes DP, Heijboer H, Buller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992;327:1485-9.
268. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med 1993; 119:874-81.
269. Lagerstedt C, Olsson CG, Fagher B, Oqvist B, Albrechtsson U. Oral anticoagulants in calf-vein thrombosis. Lancet 1985;2:1311-2.
270. Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985;2:515-8.
271. Hull R, Delmore T, Genton E, Hirsh J, Gent M, Sackett D et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979;301:855-8.
272. Palareti G, Legnani C, Cosmi B, Valdre L, Lunghi B, Bernardi F et al. Predictive value of D-dimer test for recurrent venous thromboembolism. after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003;108:313-8.
273. Heit JA. Mapping out the future in venous thromboembolism and acute coronary syndromes. Semin Thromb Hemost 2002;28 Suppl 3:33-9.
274. Bauer KA. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 2001;135:367-73.
275. Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev 2000: CD001367.
276. Prandoni P, Lensing AW, Prins MH, Bernardi E, Marchiori A, Bagatella P et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002;137:955-60.
277. Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001;103:2453-60.
278. Prandoni P, Lensing AW, Bernardi E, Villalta S, Bagatella P, Girolami A. The diagnostic value of compression ultrasonography in patients with suspected recurrent deep vein thrombosis. Thromb Haemost 2002;88:402-6.
279. Piovella F, Crippa. L, Barone M, Vigano D'Angelo S, Serafini S, Galli L et al. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica 2002;87:515-22.
280. Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002;87:7-12.
281. Fattorini A, Crippa L, Vigano' D'Angelo S, Pattarini E, D'Angelo A. Risk of deep vein thrombosis recurrence: high negative predictive value of D-dimer performed during oral anticoagulation. Thromb Haemost 2002;88:162-3.
282. Kalodiki E, Calahoras L, Nicolaides AN. Make it easy: duplex examination of the venous system. Phlebology 1993;8:17-21.
283. Prandoni P, Cogo A, Bernardi E, Villalta S, Polistena P, Simioni P et al. A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Circulation 1993;88:1730-5.
284. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119:176S-193S.
285. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995;332:1661-5.
286. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-7.
287. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001;345:165-9.
288. Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003;139:19-25.
289. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003;139:893-900.
290. Makris M, Rosendaal FR, Preston FE. Familial thrombophilia: genetic risk factors and management. J Intern Med Suppl 1997;740:9-15.
291. Tosetto A, Missiaglia E, Frezzato M, Rodeghiero F. The VITA project: prothrombin G20210A mutation and venous thromboembolism in the general population. Thromb Haemost 1999;82:1395-8.
292. van den Belt AG, Sanson BJ, Simioni P, Prandoni P, Buller HR, Girolami A et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med 1997;157:2227-32.
293. Simioni P, Prandoni P, Lensing AW, Scudeller A, Sardella C, Prins MH et al. The risk of recurrent venous thromboembolism in patients with an Arg506≥Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997;336:399-403.
294. Simioni P, Prandoni P, Lensing AW, Manfrin D, Tormene D, Gavasso S et al. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood 2000;96:3329-33.
295. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995;92:2800-2.
296. Miles JS, Miletich JP, Goldhaber SZ, Hennekens; CH, Ridker PM. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol 2001;37:215-8.
297. Eichinger S, Pabinger I, Stumpflen A, Hirschl M, Bialonczyk C, Schneider B et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997;77:624-8.
298. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost 1999;81:684-9.
299. Margaglione M, D'Andrea G, Colaizzo D, Cappucci G, del Popolo A, Brancaccio V et al. Coexistence of Factor V Leiden and Factor II A20210 mutations and recurrent venous thromboembolism. Thromb Haemost 1999;82:1583-7.
300. De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999;341:801-6.
301. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003;362:523-6.
302. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997;95:1777-82.
303. Meinardi JR, Middeldorp S, de Kam PJ, Koopman MM, van Pampus EC, Hamulyak K et al. The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. Br J Haematol 2002;116:625-31.
304. den Heijer M, Blom HJ, Gerrits WB, Rosendaal FR, Haak HL, Wijermans PW et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995;345:882-5.
305. Eichinger S, Stumpflen A, Hirschl M, Bialonczyk C, Herkner K, Stain M et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998;80:566-9.
306. Ridker PM, Goldhaber SZ, Glynn RJ. Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:2164-7; author reply 2164-7.
307. Keaton C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:631-9.
308. Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713-21.
309. PERSIST I. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. J Thromb Haemost 2004;2:47-53.
310. Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997;336:393-8.